Literature DB >> 25110244

Perivascular Epithelioid Cell Tumor (PEComa) of the Uterine Cervix in a Patient with Tuberous Sclerosis Complex: A Literature Review.

Handan Çelik1, Mehmet Kefeli, Mehmet Çetinkaya, Levent Yildiz.   

Abstract

Perivascular epithelioid cell tumors (PEComa) are a rare type of mesenchymal tumor arising from perivascular epithelial cells. These tumor cells are a co-expression of both melanocytic and myogenic antigens, such as HMB 45 and smooth muscle actin, and at least in some patients, are located around vessels. PEComas has been reported at various sites, including visceral organs, soft tissue, the prostate gland and broad ligaments. In the female reproductive system, the uterine corpus is the most common site of involvement. Some cases are related to tuberous sclerosis complex. Cervical PEComa with tuberous sclerosis complex is presented in the case of a 41 year-old and the literature is reviewed. There have been only eight cases of cervical PEComas and only one other case associated with tuberous sclerosis complex reported to date.

Entities:  

Mesh:

Year:  2018        PMID: 25110244     DOI: 10.5146/tjpath.2014.01274

Source DB:  PubMed          Journal:  Turk Patoloji Derg        ISSN: 1018-5615


  3 in total

Review 1.  Perivascular epithelioid tumours (PEComas) of the gynaecological tract.

Authors:  Niamh Conlon; Robert A Soslow; Rajmohan Murali
Journal:  J Clin Pathol       Date:  2015-03-06       Impact factor: 3.411

2.  Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model.

Authors:  Shilpa Prabhakar; Xuan Zhang; June Goto; Sangyeul Han; Charles Lai; Roderick Bronson; Miguel Sena-Esteves; Vijaya Ramesh; Anat Stemmer-Rachamimov; David J Kwiatkowski; Xandra O Breakefield
Journal:  Neurobiol Dis       Date:  2015-05-24       Impact factor: 5.996

3.  Perivascular epithelioid cell tumour and mesonephric adenocarcinoma of the uterine cervix: an unknown co-existence.

Authors:  Dimitrios Papoutsis; Banchhita Sahu; Joanna Kelly; Angeliki Antonakou
Journal:  Oxf Med Case Reports       Date:  2019-01-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.